Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Options activity at HLN has turned unusually bearish just as the lending market moves sharply in the other direction. That contrast between a put-call ratio spike and a rapidly loosening borrow pool makes this convergence worth examining closely.
The put-call ratio hit 0.0341 on October 9, a reading 2.73 standard deviations above its 20-day mean of 0.0235. That is the highest options-implied bearish skew in several weeks. Yet the same period has seen the short book shrink materially. Shares short dropped from around 18.9 million on October 7 to roughly 18.6 million by October 9, before bouncing back to approximately 22.1 million by the end of that session. The month-on-month change remains a doubling, up 109% over 30 days, so the broader trend in short positioning is still building even as individual sessions show covering.
With a 52-week high on the PCR at 0.5432, today's reading of 0.0341 is not extreme in absolute terms. The signal is the pace of the move relative to recent history, not the level itself.
The bigger structural shift is in the lending pool. In late September, availability had compressed to as low as 28.7% of short interest on September 22, meaning lenders had fewer shares available than were already borrowed. By October 9 that figure had surged to 1,109.5%. There are now roughly eleven shares available to borrow for every one currently lent out.
Cost to borrow rose 70% week-on-week to 0.54%, but that remains a low absolute level. The direction is upward, yet the borrow is not under any meaningful stress at current rates.
The ORTEX short score has also moved. It stood at 43.3 on September 25 and has fallen steadily to 30.7 by October 8, reflecting the easing borrow conditions and partial short covering over that window.
One structural backdrop worth noting: Pfizer filed a Schedule 13D/A on Haleon as recently as March 2025, having first filed in January 2025. As last disclosed, Pfizer held approximately 7.3% of the class. Schedule 13D/G positions are event-driven disclosures and stakes are "as last disclosed". Pfizer's residual presence on the register has been a persistent feature of the ownership story since Haleon's separation.
BlackRock added roughly 30 million shares as of September 30, lifting its position to 8.47% of shares. Amundi added approximately 70.8 million shares to reach 1.86% as of the same date.
Haleon's next scheduled earnings print is October 30. The stock fell nearly 4% in the session following its July 2026 results. A put-call ratio spike arriving three weeks before results, with short interest still running at elevated 30-day levels, is worth tracking as the date approaches.
Data summary:
See the live data behind this article on ORTEX.
Open HLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
